Anaïs Oudin

ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.

This study develops and tests a dual strategy using NaMiX and TriKE to enhance NK cell cytotoxicity against PDAC, showing improved tumor cell killing in vitro and in humanized mouse models.

This study develops humanized glioblastoma PDOX models to study tumor-immune interactions and test immunotherapies in a human context.

This study integrates multi-omics and functional drug screening in patient-derived organoids to identify personalized therapeutic vulnerabilities in adult high-grade gliomas, finding distinct drug responses in IDH1 mutant and MYCN-amplified tumors.

This study shows that adenoviral delivery of CIITA enhances T-cell mediated killing of glioblastoma organoids, with some MHC-II-independent immune responses observed.